What people are saying - Write a review
We haven't found any reviews in the usual places.
Initial Clinical Dose Norman E Pitts
Phase I Drug Study Anthony W Czerwinski
Evaluation of Agents which Stimulate
4 other sections not shown
acid activity administration Adult Males 50 adverse reaction agents agranulocytosis allergic aminopyrine anemia animal data animal models antipyrine arsenicals associated barbiturates bilirubin bone marrow bromides cancer Captive and Non-captive captive group carcinogenic chemical chlorpromazine chromosome chronic clinical compound CPZ sensitive patients cutaneous cytogenetic determined develop differences dosage drug eruptions drug reactions drug-induced effect erythema multiforme erythropoietin evaluation experimental factors Figure Frequency Distribution Curves genetic gold salts Healthy Adult Males Hematocrit hepatitis hepatotoxic human dose human toxic incubation induced injection investigator iodides labeling index laboratory lesions leukocytes liquid silicone marrow cells maximum tolerated dose Medical metabolism monitoring mutagenic non-captive group Non-captive Healthy Adult Normal Range observed occur penicillin percent perphenazine Pharmacol pharmacological Phase phenothiazines phenylbutazone plasma potential predictions produce protein purpura quinacrine rats red cell Research salicylates serum serum sickness skin species studies subjects sulfonamides surface area testing therapeutic therapy tion tissue toxicological tumors urticaria values